and other immune modulators like anakinra (Kineret) and tocilizumab (Actemra). They noted that getting the word out about a potential uptick in cases might help community physicians better ...

Cognitively impaired patients with CKD more frequently experience a host of health problems and are at higher risk for death. Cognitive impairment in patients with chronic kidney disease (CKD) is ...

Cancer is disrupting the lives of many people around the world, including India; one of them is bladder cancer. However, now there is hope for its treatment through the proteins present in breast milk ...

Microglia, Pediatric Neurology, Autism Spectrum Disorder, Epilepsy, Neuroinflammation, Neurodevelopment Kaur, H. (2025) The Role of Microglia in Pediatric Neurological Disorders. Neuroscience and ...

A study in Germany saw 20 patients with acute cystitis - a bladder infection mainly caused by E coli bacteria - injected with the drug anakinra (IL-1RA), another normal component of human breast milk.

Cardiol’s focus on anti-inflammatory and anti-fib MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra ...

Anakinra failed to reduce cytokine release syndrome or immune effector cell–associated neurotoxicity in patients with large B-cell lymphoma receiving liso-cel. Using the interleukin-1 receptor ...

Conclusion The main preliminary findings of this global registry suggest that an early introduction of anakinra in patients with RP, corticosteroid-dependent and not responding to colchicine, ...

Objective: To examine the therapeutic effect of the interleukin 1 (IL1) receptor antagonist anakinra in ankylosing spondylitis in an open label trial. Methods: Anakinra (100 mg) was given ...

Notably, she advanced the translational research pipeline for anakinra in acute stroke, in ischaemic stroke (phase 2), and in aneurysmal subarachnoid haemorrhage (a recently completed phase 3 trial).

This study provides a comprehensive exploration of the role of IL-1β signaling during development of lung injury induced by a combination of underlying inflammation and mechanical ventilation. The ...

Kiniksa has interacted with the U.S. Food and Drug Administration (FDA) and expects to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data expected ...